Ongoing Clinical Trials for Staphylococcal Bacteraemia
Five clinical trials are currently investigating different antibiotic treatments for staphylococcal bacteraemia, a serious blood infection caused by Staphylococcus aureus bacteria. These studies are exploring optimal treatment durations, dosing strategies, and drug combinations to improve patient outcomes. Trials are taking place across Denmark, Germany, the Netherlands, and Sweden.
Clinical trial locations
- Denmark
- Germany
- Netherlands
- Sweden
- Study Comparing Benzylpenicillin and Cloxacillin for Treating Staphylococcus Aureus Blood Infection in Patients
- Study on How Kidney Function Estimates Help Adjust Cloxacillin Dosing in Patients with Staphylococcus aureus Bacteremia
- Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia
Study Comparing Benzylpenicillin and Cloxacillin for Treating Staphylococcus Aureus Blood Infection in Patients
This trial is comparing two antibiotics, benzylpenicillin and cloxacillin, for treating penicillin-susceptible Staphylococcus aureus bloodstream infections. Both medications are administered directly into the bloodstream through a vein.
Who can participate: Adults over 18 years old with confirmed penicillin-susceptible Staphylococcus aureus in their blood who can provide informed consent. Both men and women may join.
Who cannot participate: People with allergies to penicillin or cloxacillin, those with a history of severe allergic reactions to antibiotics, pregnant or breastfeeding women, individuals with liver or kidney problems, those currently in another clinical trial, people with weakened immune systems, recent heart attack or stroke survivors, those with uncontrolled diabetes, individuals with drug or alcohol abuse history, and those unable to follow study procedures.
Treatment approach: Participants are randomly assigned to receive either benzylpenicillin or cloxacillin for up to seven days. The study monitors patients for 90 days after treatment to assess recovery and watch for any complications or infection relapse. Both antibiotics work by breaking down bacterial cell walls, ultimately destroying the bacteria causing the infection.
Study on How Kidney Function Estimates Help Adjust Cloxacillin Dosing in Patients with Staphylococcus aureus Bacteremia
This study examines whether kidney function measurements can help determine when patients need adjusted doses of cloxacillin, an antibiotic used to treat bloodstream infections. The research involves monitoring drug levels in the blood to ensure they remain within safe and effective ranges.
Who can participate: Adults 18 years or older who have tested positive for Staphylococcus aureus in a blood culture taken within the past 72 hours and who have started or will start cloxacillin treatment within that timeframe. Written consent is required.
Who cannot participate: People without confirmed infection, those younger than 18 or older than 65, and individuals considered part of vulnerable populations who cannot make decisions for themselves.
Treatment approach: Participants receive cloxacillin intravenously. Blood tests on days 2 and 7 measure drug levels and kidney function. Daily monitoring from day 1 to day 7 checks for signs of kidney injury and any effects on the nervous system, such as changes in consciousness or seizures. The study aims to finish by June 2026 and will help determine if standard dosing needs adjustment based on individual kidney function.
Study on Reducing Antibiotic Duration for Patients with Complicated Staphylococcus aureus Bacteremia Using Cefazolin Sodium, Flucloxacillin Sodium Monohydrate, and Clindamycin
This trial investigates whether four weeks of antibiotic treatment is as effective as the traditional six-week course for patients with complicated infections who have responded well to initial therapy. The antibiotics being studied include cefazolin sodium, flucloxacillin sodium monohydrate, and clindamycin.
Who can participate: Adults with methicillin-sensitive complicated infection, meaning the bacteria can be treated with certain antibiotics and the infection affects organs or has spread deeply into the body. This includes conditions like heart lining infection, spine infection, joint infection, blood vessel infection, or abscesses. Participants must have at least one positive blood test, meet certain risk factors, and show good response to initial treatment, including negative blood tests by day 8, reduced inflammation markers, and no fever between days 7 and 14 of treatment. Both men and women may participate.
Who cannot participate: Those who haven’t responded well to initial treatment and people from vulnerable populations.
Treatment approach: Patients showing satisfactory early response are randomly assigned to receive either four or six weeks of total antibiotic treatment. They are monitored for 180 days after treatment begins to ensure they remain alive and free from disease relapse, confirmed by the absence of bacteria in blood or other sterile sites.
Study on the Effect of Rifampicin and Drug Combination for Patients with Staphylococcus aureus Bacteremia
This large trial evaluates various antibiotic treatments to determine their impact on patient survival over 90 days. The study includes multiple medications: Rifampicin, Doxycycline, Co-trimoxazole, Cefazolin, Flucloxacillin, Daptomycin, Benzylpenicillin Sodium, Amoxicillin, Levofloxacin, Clindamycin, Cefalexin, Moxifloxacin, Linezolid, Clindamycin Hydrochloride, and Vancomycin. Some participants will receive a placebo for comparison.
Who can participate: Adults admitted to participating hospitals who have confirmed Staphylococcus aureus bacteria in at least one blood culture. Both men and women may join.
Who cannot participate: People under 18 or over 65 years old, pregnant or breastfeeding women, those with severe allergies to study medications, current participants in other clinical trials, people with medical conditions making participation unsafe, those with a history of drug or alcohol abuse, and individuals with different types of infections other than the one being studied.
Treatment approach: Participants are randomly assigned to receive one of the listed antibiotics through oral, intravenous, or IV infusion routes, depending on the medication. Health is closely monitored throughout the trial, with follow-up assessments at 14, 28, 42, and 90 days to evaluate treatment effectiveness and identify any side effects. The various antibiotics work by different mechanisms, including stopping bacterial growth, killing bacteria, or preventing bacterial cell wall synthesis.
Study on the Effectiveness of Clarithromycin and Other Drug Combinations for Patients with Uncomplicated Staphylococcus aureus Blood Infection
This trial compares seven versus fourteen days of antibiotic treatment for uncomplicated bloodstream infections to determine which duration is more effective. The antibiotics include Clarithromycin, Meropenem, Ceftriaxone, Cefotaxime, Piperacillin/Tazobactam, Vancomycin, Dicloxacillin, Flucloxacillin, Linezolid, Clindamycin, Levofloxacin, Moxifloxacin, Amikacin, Gentamicin, Benzylpenicillin, Cloxacillin, and Daptomycin.
Who can participate: Adults 18 years or older with confirmed Staphylococcus aureus in blood tests who started appropriate antibiotic treatment within 12 hours of the first positive test. Participants must have a body temperature below 37.8°C at enrollment and a follow-up blood test showing no bacteria between 48 to 120 hours after initial diagnosis.
Who cannot participate: Those with different types of infections and people from vulnerable populations requiring special protection or care.
Treatment approach: Participants are randomly assigned to receive either seven or fourteen days of antibiotic treatment. They are monitored for 90 days after diagnosis for signs of clinical or microbiological failure. The study evaluates whether a shorter treatment duration is as effective as a longer one in preventing death and infection recurrence, which could help reduce side effects and healthcare costs.
Summary
These five clinical trials represent comprehensive research efforts to optimize antibiotic treatment for staphylococcal bacteraemia. Three trials are being conducted in Sweden, two in the Netherlands, and one each in Germany and Denmark, showing particularly strong research activity in Scandinavian countries.
A common theme across the studies is the investigation of treatment duration, with multiple trials questioning whether shorter courses of antibiotics might be as effective as traditional longer regimens. This research direction could have important implications for reducing side effects and healthcare costs.
Cloxacillin and related antibiotics appear frequently across the trials, reflecting their established role in treating these infections. Several studies also explore how individual patient characteristics, particularly kidney function, should influence treatment decisions. The large multi-country trial examining numerous antibiotics demonstrates the international collaborative effort to identify the most effective treatments for this serious condition.